key: cord-0834112-pxzxh8g1
authors: Pham, Khanh; Torres, Heidi; Satlin, Michael J; Goyal, Parag; Gulick, Roy M
title: Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
date: 2021-03-02
journal: Rheumatol Adv Pract
DOI: 10.1093/rap/rkab014
sha: cdf43ad8cca7e79a42fe165e3dd68cd1440bc7fe
doc_id: 834112
cord_uid: pxzxh8g1

OBJECTIVE: To compare baseline characteristics, clinical presentations, and outcomes of patients with rheumatic conditions requiring hospitalization for COVID-19 who received chronic hydroxychloroquine to those who did not receive chronic hydroxychloroquine. METHODS: We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between March 3-April 30 2020. Patients who received chronic hydroxychloroquine prior to admission were matched 1:2 (±10 years of age) to patients who did not receive chronic hydroxychloroquine. We compared demographics, comorbidities, hydroxychloroquine dosages, concurrent medications, presentations, and outcomes between the groups. RESULTS: There were 14 patients receiving hydroxychloroquine and 28 matched control subjects. The median age of cases was 63 years (IQR 43–73) and 60 years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%), and obesity (35.7%) than their case counterparts (28.6%, 14.3%, and 7.1%, respectively). A higher proportion of case than control subjects (50% vs.s 25%) reported usage of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation (OR 1.5; 95% CI: 0.34–6.38) or in-hospital mortality (OR 0.77; 95% CI: 0.13–4.56). CONCLUSION: Hydroxychloroquine therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving hydroxychloroquine.

Coronavirus disease 2019 (COVID-19) is a highly transmissible disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first detected in Wuhan, China in December 2019 (1) and has rapidly become a pandemic with over 81.5 million cases and 1.7 million deaths worldwide as of late December 2020 (2) . SARS-CoV-2 often causes a viral pneumonia with frequent complications, such as hypoxic respiratory failure, acute respiratory distress syndrome, coagulation dysfunction, cytokine storm syndrome, multiorgan failure, and death (3, 4) . Several drugs have been investigated to treat and prevent this disease. With the exception of vaccines that have recently been granted emergency use authorization (EUA) status by the United States Food and Drug Administration (U.S. FDA), there is no other effective preventive agent for COVID-19 (5) .

Hydroxychloroquine (HCQ) is U.S. FDA-approved for malaria and some rheumatic diseases, but also demonstrates in vitro activity against SARS-CoV-2 (6, 7) . Since the onset of the pandemic, however, numerous randomized controlled trials have found that HCQ is unlikely to be beneficial as a therapeutic agent when used in hospitalized patients with COVID-19 (8) (9) (10) (11) (12) (13) . One study even reported that among patients who did not undergo mechanical ventilation at baseline, https://mc.manuscriptcentral.com/rheumap those in the HCQ group, as compared to the usual care group, had a higher frequency of invasive mechanical ventilation or death (13) .

There are studies that have also assessed the preventive effects of HCQ in COVID-19. One randomized controlled trial that evaluated the efficacy and safety of HCQ for pre-exposure SARS-CoV-2 prophylaxis among health care workers found that daily HCQ did not prevent infection, although this study was terminated early and did not reach enrollment targets (14) . In particular, the efficacy of HCQ in the rheumatic patient population has only been reported in a small number of studies (15) (16) (17) (18) (19) (20) with most demonstrating no benefit of HCQ in preventing hospital admission with COVID-19, except for one study that reported a lower risk of COVID-19 in patients taking HCQ as compared to patients taking disease-modifying anti-rheumatic drugs (20) . In our study, we compared the baseline characteristics, clinical presentations, and outcomes of patients with rheumatic conditions requiring hospitalization for COVID-19 who received chronic hydroxychloroquine to those who did not receive chronic hydroxychloroquine.

We reviewed the medical records of all patients who presented to NewYork-Presbyterian Hospital/Weill Cornell Medical Center (quaternary referral center) and affiliated Lower Manhattan Hospital (community hospital) from March 3 to April 30, 2020 with confirmed COVID-19, defined as having SARS-CoV-2 nucleic acid detected by reverse transcriptionpolymerase chain reaction (RT-PCR) using a nasopharyngeal swab sample. We identified the proportion of these patients who were hospitalized and had underlying rheumatic diseases, and divided them into individuals who were receiving chronic HCQ (cases) versus those not receiving the drug (controls). A random number generator was used to individually match two eligible control patients to each eligible case patient within the same 10-year age category, thereby achieving a 2:1 matching by age (±10 years). We then reviewed the electronic medical record to report on the demographics, underlying comorbidities, HCQ dosages, concurrent medications, presentations, and outcomes of these two groups. All patients were followed until hospital discharge. We applied descriptive statistics, using medians for continuous variables and proportions for categorical variables, and used univariate logistic regression to analyze the outcomes. Stata 16.1 software was used for all analyses. This study was approved by the Institutional Review Board at Weill Cornell Medicine with a waiver of informed consent. reported other rheumatic conditions. By comparison, 11 (39.3%) control subjects had rheumatoid arthritis, 2 (7.1%) had systemic lupus erythematosus, and 16 (57.1%) reported other rheumatic conditions, which included psoriasis, mixed connective tissue disease, vasculitides, and other autoimmune conditions. Case individuals were receiving 200 or 400 milligrams of daily HCQ for at least 4 weeks prior to presentation. A significant proportion of case and control individuals reported taking other concurrent immunomodulating agents prior to admission. Notably, a larger proportion of case subjects (50%) than controls (25%) received prednisone prior to presentation.

Common comorbid illnesses included hypertension, coronary artery disease, diabetes, end-stage renal disease, obesity, congestive heart failure, and various pulmonary diseases in both groups.

Control subjects had a higher prevalence of diabetes (35.7%) and obesity (35.7%) than the case counterparts (14.3% and 7.1%, respectively). Additionally, a larger proportion of control subjects (42.8%) than cases (28.6%) had a history of pulmonary disease, which included chronic obstructive pulmonary disease, asthma, interstitial lung disease, and other pulmonary conditions. Common presenting symptoms between the two groups were dyspnea, fever, cough, diarrhea, and nausea or vomiting. Controls were more likely to have chest pain, headache, sore throat, altered mental status, ageusia, rhinorrhea, and anosmia than case subjects. The majority of individuals in both groups had radiographic findings of bilateral pulmonary opacities consistent with viral pneumonia. Of the 14 case individuals, 6 (42.9%) required oxygen support within the first 3 hours of hospital arrival, as compared to 17 Regarding the rest of the hospital course, there were similar rates of intubation and ICU admission between the cases and controls (28.6% and 21.4%, respectively). Of the 4 case patients requiring intensive care unit (ICU) admission, 3 (75%) were eventually discharged from the ICU. In comparison, 4 (67%) of the 6 control patients were in stable condition to eventually leave the ICU. Overall, 14.3% of case patients died during their hospitalization, as compared to 17.9% of control patients. When analyzed by univariate logistic regression, there were no statistical differences noted in the need for mechanical ventilation (OR 1.5; 95% CI: 0.34-6.38) or in-hospital mortality (OR 0.77; 95% CI: 0.13-4.56) between the two groups.

Thus far in the COVID-19 pandemic, vaccines are the only proven agents to prevent COVID-19 (5) . While numerous randomized clinical trials have found that HCQ is ineffective as a therapeutic and preventive agent (8) (9) (10) (11) (12) (13) (14) , fewer have studied the effects of this agent as preexposure prophylaxis in the rheumatic patient population (15) (16) (17) (18) (19) (20) . Our study is one of a small number of studies to show that use of chronic HCQ for a variety of rheumatic diseases failed to prevent COVID-19 (15) (16) (17) (18) (19) (20) .

Our study illustrates several important findings. First, our patients were racially and ethnically diverse and nearly all had comorbid illnesses considered to be risk factors for developing severe COVID-19, such as diabetes, hypertension, obesity, and chronic heart, lung, and kidney diseases (3, 4) . In addition, a significant proportion of individuals in each group were receiving other concurrent immunomodulating agents prior to admission that may also increase the risk of acquiring and developing severe COVID-19 (19) . It should also be noted that the prevalence of diabetes, obesity, and pulmonary diseases was higher in control than case patients. Additionally, a much higher proportion of case individuals, as compared to control individuals, received corticosteroids before and during their hospitalization. Despite these baseline differences, there were no statistical differences observed in the outcomes between these groups, which included no differences in complication rates, need for mechanical ventilation or ICU care, in-hospital mortality, or hospital discharge. Although there were no statistical differences observed in hospital outcomes, our findings may still help clinicians to identify vulnerable patients who may still be at risk for developing severe COVID-19 illness.

Our study has several limitations: First, our sample size was small, which limited our ability to detect potential differences between groups and adjust for potential confounders, and evaluated patients from only two hospitals. Second, adherence to HCQ among case patients prior to admission was not examined-individual HCQ regimen and history were obtained from chart review, which did not assess for medication adherence.

In summary, our study suggests that chronic HCQ use for rheumatic diseases did not prevent development of severe COVID-19 when compared to a control group who was not receiving chronic HCQ. These data, combined with other data that have not identified a protective effect of HCQ, inform clinicians that patients with rheumatic diseases who are taking long-term HCQ should be monitored closely for severe illness if they develop COVID-19. 

Pneumonia of unknown cause -China

An interactive web-based dashboard to track COVID-19 in real time

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china

Clinical Characteristics of Covid-19 in New York City

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. Open Forum Infect Dis

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology

Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis

Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. The Lancet Rheumatology

This study received support from NewYork-Presbyterian Hospital (NYPH) and Weill Cornell